1160 related articles for article (PubMed ID: 35088968)
21. An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey.
Çağlayan D; Süner AF; Şiyve N; Güzel I; Irmak Ç; Işik E; Appak Ö; Çelik M; Öztürk G; Alp Çavuş S; Ergör G; Sayiner A; Ergör A; Demiral Y; Kiliç B
J Med Virol; 2022 May; 94(5):2212-2221. PubMed ID: 35075655
[TBL] [Abstract][Full Text] [Related]
22. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
23. Antibody responses to COVID-19 vaccines in older adults.
Bag Soytas R; Cengiz M; Islamoglu MS; Borku Uysal B; Yavuzer S; Yavuzer H
J Med Virol; 2022 Apr; 94(4):1650-1654. PubMed ID: 34921432
[TBL] [Abstract][Full Text] [Related]
24. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
25. Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination.
Wang F; Huang B; Lv H; Feng L; Ren W; Wang X; Tang L; Liu Q; Wu D; Zheng H; An Z; Deng Y; Zhao L; Ye F; Wang W; Zhang H; Chang S; Liao Y; Chen F; Rodewald LE; Gao GF; Yin Z; Tan W
Front Immunol; 2022; 13():967051. PubMed ID: 36159863
[TBL] [Abstract][Full Text] [Related]
26. Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study.
Kuloğlu ZE; El R; Guney-Esken G; Tok Y; Talay ZG; Barlas T; Kuskucu MA; Albayrak Ö; Doğan Ö; Yavuz SŞ; Midilli K; Ergönül Ö; Can F
Allergy; 2022 Aug; 77(8):2459-2467. PubMed ID: 35437772
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial.
Omma A; Batirel A; Aydin M; Yilmaz Karadag F; Erden A; Kucuksahin O; Armagan B; Güven SC; Karakas O; Gokdemir S; Altunal LN; Buber AA; Gemcioglu E; Zengin O; Inan O; Sahiner ES; Korukluoglu G; Sezer Z; Ozdarendeli A; Kara A; Ates I
Hum Vaccin Immunother; 2022 Nov; 18(6):2122503. PubMed ID: 36315843
[TBL] [Abstract][Full Text] [Related]
28. Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients.
Eren Sadioğlu R; Demir E; Evren E; Aktar M; Şafak S; Artan AS; Meşe S; Ağaçfidan A; Çınar G; Önel M; Karahan ZC; Şengül Ş; Keven K; Türkmen A
Transpl Infect Dis; 2021 Dec; 23(6):e13740. PubMed ID: 34606134
[TBL] [Abstract][Full Text] [Related]
29. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
Casas Fischer R
Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
[TBL] [Abstract][Full Text] [Related]
30. Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required.
Balkan İİ; Dinc HO; Can G; Karaali R; Ozbey D; Caglar B; Beytur AN; Keskin E; Budak B; Aydogan O; Mete B; Ergin S; Kocazeybek B; Saltoglu N
Ir J Med Sci; 2023 Feb; 192(1):19-25. PubMed ID: 35344137
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers.
Marra AR; Miraglia JL; Malheiros DT; Guozhang Y; Teich VD; da Silva Victor E; Pinho JRR; Cypriano A; Vieira LW; Polonio M; Ornelas RH; de Oliveira SM; Borges Junior FA; Shibata ARO; Schettino GPP; de Oliveira KG; Ferraz Santana RA; de Mello Malta F; Amgarten D; Boechat AL; Trecenti NMZ; Kobayashi T; Salinas JL; Edmond MB; Rizzo LV
Infect Control Hosp Epidemiol; 2023 Jan; 44(1):75-81. PubMed ID: 35351217
[TBL] [Abstract][Full Text] [Related]
32. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study.
Hitchings MDT; Ranzani OT; Torres MSS; de Oliveira SB; Almiron M; Said R; Borg R; Schulz WL; de Oliveira RD; da Silva PV; de Castro DB; Sampaio VS; de Albuquerque BC; Ramos TCA; Fraxe SHH; da Costa CF; Naveca FG; Siqueira AM; de Araújo WN; Andrews JR; Cummings DAT; Ko AI; Croda J
Lancet Reg Health Am; 2021 Sep; 1():100025. PubMed ID: 34386791
[TBL] [Abstract][Full Text] [Related]
34. Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience.
Yigit M; Ozkaya-Parlakay A; Cosgun Y; Ince YE; Bulut YE; Senel E
J Med Virol; 2022 Jan; 94(1):287-290. PubMed ID: 34487373
[TBL] [Abstract][Full Text] [Related]
35. Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021.
Kwok SL; Cheng SM; Leung JN; Leung K; Lee CK; Peiris JM; Wu JT
Euro Surveill; 2022 Jan; 27(2):. PubMed ID: 35027105
[TBL] [Abstract][Full Text] [Related]
36. A longitudinal study of humoral immune responses induced by a 3-dose inactivated COVID-19 vaccine in an observational, prospective cohort.
Tao Y; Ma M; Hu F; Li M; Geng Y; Wan Y; Mao M; Chen L; Shen Y; Zhu L; Shen H; Chen Y
BMC Immunol; 2022 Nov; 23(1):57. PubMed ID: 36384440
[TBL] [Abstract][Full Text] [Related]
37. Comparison of antibody responses following natural infection with Severe Acute Respiratory Syndrome Coronavirus 2 or receipt of CoronaVac or ChAdOx1 (AZD1222) vaccination in Chiang Mai, Thailand.
Hongjaisee S; Chawansuntati K; Sripan P; Rattanathammethee K; Sakkhachornphop S; Chaiwarith R; Sudjaritruk T; Supparatpinyo K; Wipasa J
Vaccine X; 2023 Aug; 14():100305. PubMed ID: 37155476
[TBL] [Abstract][Full Text] [Related]
38. Antibody Responses and Reactogenicity of a Heterologous, Full-Dose Messenger RNA-1273 Booster in Heavily SARS-CoV-2-Exposed CoronaVac-Vaccinated Health-Care Workers in Indonesia: A Real-World Observational Study.
Sinto R; Utomo D; ; Nelwan EJ; Surendra H; Natasha C; ; Theresia D; Ranitria AF; Subekti D; Nuraeni N; Handayani W; Rahardjani M; Baird JK; Dunachie S; Shankar AH; Hamers RL
Am J Trop Med Hyg; 2023 Jan; 108(1):115-123. PubMed ID: 36450232
[TBL] [Abstract][Full Text] [Related]
39. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study.
Hua Q; Zhang H; Yao P; Xu N; Sun Y; Lu H; Xu F; Liao Y; Yang J; Mao H; Zhang Y; Zhu H; Hu X; Lv H; Jiang J
Front Immunol; 2022; 13():939311. PubMed ID: 36032136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
